CLDX · Celldex Therapeutics, Inc. · Investor Relations

$31.24 +1.37 (+4.59%) Q4 2021 earnings call transcript

Russell 2000 member Rebalance outlook locked

Market Cap

$2.35B

78.55M

Volume · Nov 9 1.59M Avg daily vol (3M) 1.35M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date	Headline
2026-11-05	Celldex Reports Third Quarter Financial Results and Provides Corporate Update
2026-09-22	Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints
2026-08-06	Celldex Reports Second Quarter Financial Results and Provides Corporate Update
2026-05-07	Celldex Reports First Quarter Financial Results and Provides Corporate Update
2026-04-02	Celldex Announces Pricing of $300 Million Public Offering of Common Stock
2026-04-02	Celldex Announces Proposed Public Offering of Common Stock
2026-02-25	Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
2025-11-10	Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Past events

Date	Event	Type
2026-09-22	Topline Phase 3 EMBARQ CSU1 and CSU2 Results Call	Earnings call
2026-09-10	Cantor Global Healthcare Conference	Conference
2026-07-21	Phase 2 Topline PN Results Conference Call and Webcast	Earnings call
2026-04-14	H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference	Conference

Source: https://ir.celldex.com/

Key facts CIK 744218 CUSIP 15117B202 13F (30d) 101 filings 79 filers Visit website Investor relations